Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Sep 12 04:00PM ET
9.46
Dollar change
+0.11
Percentage change
1.18
%
IndexRUT P/E- EPS (ttm)-1.68 Insider Own18.58% Shs Outstand256.14M Perf Week-9.56%
Market Cap2.87B Forward P/E- EPS next Y-0.72 Insider Trans0.00% Shs Float247.13M Perf Month-11.92%
Income-440.22M PEG- EPS next Q-0.30 Inst Own68.27% Short Float23.34% Perf Quarter10.90%
Sales32.77M P/S87.62 EPS this Y31.97% Inst Trans-1.80% Short Ratio8.17 Perf Half Y-35.78%
Book/sh2.58 P/B3.66 EPS next Y44.22% ROA-51.14% Short Interest57.69M Perf Year58.72%
Cash/sh1.36 P/C6.96 EPS next 5Y- ROE-65.36% 52W Range3.21 - 18.33 Perf YTD16.36%
Dividend Est.- P/FCF- EPS past 5Y-8.25% ROI-52.48% 52W High-48.39% Beta0.65
Dividend TTM- Quick Ratio4.85 Sales past 5Y0.00% Gross Margin-124.49% 52W Low194.70% ATR (14)0.66
Dividend Ex-Date- Current Ratio5.15 EPS Y/Y TTM25.12% Oper. Margin-1401.36% RSI (14)42.23 Volatility7.74% 6.03%
Employees557 Debt/Eq0.11 Sales Y/Y TTM13669.75% Profit Margin-1343.27% Recom1.50 Target Price22.90
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q28.17% Payout- Rel Volume0.55 Prev Close9.35
Sales Surprise26.47% EPS Surprise3.82% Sales Q/Q12969.75% EarningsAug 08 AMC Avg Volume7.06M Price9.46
SMA20-12.79% SMA500.40% SMA200-7.21% Trades Volume3,968,165 Change1.18%
Date Action Analyst Rating Change Price Target Change
Jul-29-24Downgrade Piper Sandler Overweight → Neutral $19 → $10
Nov-20-23Initiated Goldman Buy $12
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Jan-28-22Upgrade Stifel Hold → Buy $23 → $25
Sep-06-24 09:30AM
Sep-03-24 05:00PM
Sep-02-24 06:15PM
Aug-27-24 04:36AM
Aug-16-24 05:00PM
07:15AM Loading…
Aug-14-24 07:15AM
Aug-09-24 12:23PM
09:27AM
Aug-08-24 05:30PM
04:24PM
04:01PM
Aug-01-24 10:01AM
Jul-31-24 05:31AM
Jul-29-24 06:24PM
04:01PM
08:31AM Loading…
08:31AM
Jul-19-24 05:00PM
Jul-17-24 02:29PM
Jul-14-24 05:45AM
Jul-11-24 02:23PM
Jul-08-24 06:46PM
12:30PM
Jun-28-24 07:00AM
04:05AM
Jun-21-24 05:00PM
06:36AM
Jun-20-24 10:02PM
08:47PM
Jun-10-24 10:15AM
May-29-24 06:20AM
04:58AM Loading…
04:58AM
May-28-24 08:14AM
08:06AM
May-24-24 04:01PM
11:18AM
May-23-24 05:00PM
May-22-24 06:40AM
May-17-24 05:15PM
May-16-24 09:30AM
May-13-24 02:25PM
12:42PM
May-11-24 10:00AM
May-10-24 02:03PM
01:35PM
12:55PM
12:33PM
11:25AM
10:58AM
May-09-24 08:57PM
04:27PM
04:23PM
04:01PM
May-06-24 09:56AM
May-01-24 06:01AM
Apr-30-24 06:01AM
Apr-28-24 02:44PM
Apr-27-24 07:00AM
Apr-25-24 10:30AM
09:20AM
Apr-24-24 04:01PM
Apr-21-24 05:08AM
Apr-19-24 05:15PM
Apr-17-24 09:45AM
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Feb-29-24 05:47PM
12:17PM
10:37AM
09:44AM
05:51AM
Feb-28-24 05:35PM
04:42PM
04:35PM
04:01PM
Feb-27-24 08:52AM
Feb-26-24 05:39AM
Feb-25-24 08:07AM
05:01AM
Feb-23-24 06:14AM
Feb-22-24 08:45AM
04:00AM
Feb-20-24 03:38PM
11:02AM
08:00AM
06:30AM
Feb-19-24 08:36AM
Feb-16-24 05:30PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vogt Frederick GInterim CEO & General CounselSep 03 '24Option Exercise0.0057,2920212,175Sep 05 07:56 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerSep 03 '24Option Exercise0.0027,345071,233Sep 05 07:54 PM
BILINSKY IGORChief Operating OfficerSep 03 '24Option Exercise0.0026,954066,313Sep 05 07:53 PM
Bellemin Jean-MarcChief Financial OfficerSep 03 '24Option Exercise0.0023,438041,239Sep 05 07:52 PM
Vogt Frederick GInterim CEO & General CounselJul 15 '24Option Exercise0.0020,8350168,160Jul 17 08:01 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 15 '24Option Exercise0.002,813047,299Jul 17 08:01 PM
BILINSKY IGORChief Operating OfficerJul 15 '24Option Exercise0.002,813042,571Jul 17 08:00 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJun 03 '24Option Exercise0.003,906046,468Jun 05 08:07 PM
BILINSKY IGORChief Operating OfficerJun 03 '24Option Exercise0.003,516041,542Jun 05 08:05 PM
Vogt Frederick GInterim CEO & General CounselJun 03 '24Option Exercise0.0010,4170151,751Jun 05 08:04 PM
Vogt Frederick GInterim CEO & General CounselApr 15 '24Option Exercise0.0020,8340150,185Apr 17 07:08 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerApr 15 '24Option Exercise0.002,812043,989Apr 17 07:07 PM
BILINSKY IGORChief Operating OfficerApr 15 '24Option Exercise0.002,812039,453Apr 17 07:07 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerMar 04 '24Option Exercise0.0015,623049,230Mar 06 06:20 PM
Vogt Frederick GInterim CEO & General CounselMar 04 '24Option Exercise0.0041,6620140,800Mar 06 06:19 PM
MCPEAK MERRILL ADirectorFeb 20 '24Buy9.15250,0002,287,500320,150Feb 20 07:52 PM
Dukes Iain D.DirectorFeb 20 '24Buy9.1532,000292,80054,000Feb 20 04:21 PM
Rothbaum Wayne P.DirectorFeb 20 '24Buy9.155,000,00045,750,00028,067,333Feb 20 04:11 PM
Vogt Frederick GInterim CEO & General CounselJan 16 '24Option Exercise0.0020,8340105,668Jan 18 06:09 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 16 '24Option Exercise0.002,813035,184Jan 18 06:09 PM
BILINSKY IGORChief Operating OfficerJan 16 '24Option Exercise0.002,813031,444Jan 18 06:07 PM
Vogt Frederick GInterim CEO & General CounselOct 16 '23Option Exercise0.0020,835093,685Oct 18 08:05 PM
BILINSKY IGORChief Operating OfficerOct 16 '23Option Exercise0.002,813030,026Oct 18 08:04 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerOct 16 '23Option Exercise0.002,813033,766Oct 18 08:03 PM
MCPEAK MERRILL ADirectorSep 18 '23Buy5.5610,00055,600248,633Sep 19 04:30 PM
Rothbaum Wayne P.DirectorSep 15 '23Buy5.305,000,00026,500,00023,067,333Sep 15 06:12 PM